HCW Biologics FY 2023 net loss $25M vs $14.9M; going concern substantial doubt; $12.5M new financing

HCW Biologics Inc.

2024-Q1 EPS reported -$0.20 revenue$1,126,712

FY 2023 revenue $2.8M (down 58% from $6.7M); net loss $25.0M vs $14.9M in 2022.
Reserve for credit loss of $5.3M on terminated Prime Capital Ventures credit agreement.
Completed $2.5M private placement (Feb 2024) and $10.0M secured notes (Mar 2024); substantial doubt about going concern as of Dec 31, 2023.
Phase 1/1b trials of HCW9218 completed; planning Phase 2 in ovarian and pancreatic cancer.
Arbitration with Altor/NantCell scheduled for May 2024; new Delaware complaint for contribution of legal fees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCW Biologics Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.

Period: fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, HCW Biologics Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-039334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.